1298084-29-3

Upstream product

• 1298084-48-6 (4-(6-(3-nitrophenyl)-1H-indole-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-7-yl)methyl pivalate 
• 1266726-40-2 6-(3-nitrophenyl)-1H-indole 
• 1146629-75-5 (4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)methyl 2,2-dimethylpropanoate 
• 1298084-47-5 (4-(6-(3-aminophenyl)-1H-indole-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-7-yl)methyl pivalate 
• 700-87-8 1-Isocyanato-2-methoxy-benzene 
• 3680-69-1 4-chloro-1H-pyrrolo[2,3-d]pyrimidine 
• 13331-27-6 m-nitrobenzene boronic acid 
• 52415-29-9 6-bromo-1H-indole 

Relevant academic research and scientific papers

CML THERAPEUTIC AGENTS WITH REDUCED DRUG-RESISTANCE AND SIDE-EFFECT COMPRISING 1,6-DISUBSTITUTED INDOLE COMPOUNDS

The present invention relates to a therapeutic agent for chronic myelogenous leukemia with reduced drug-resistance and side-effects containing a 1,6-disubstituted indole compound.

NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS

Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compoun

NOVEL 1,6-DISUBSTITUTED INDOLE COMPOUNDS AS PROTEIN KINASE INHIBITORS

Disclosed are a 1,6-substituted indole compound having a protein kinase inhibition activity, a pharmaceutically acceptable salt, and a pharmaceutical composition for prevention and treatment of cancers caused by abnormal cell growth comprising the compoun